

Appendix 16.2.6 Individual efficacy response data

List 16.2.6.7 IgG concentration/cleavage.....	2
--	----------

List 16.2.6.7 IgG concentration/cleavage

Treatment	Subject	Time from dosing (h)	IgG Concentration (mg/L after first dose	IgG Concentration (mg/L)) after second dose
Group 1	101	0	12972.31	.
	101	0.2333333	8073.178	65.26251
	101	0.5	7924.254	65.42097
	101	1	8093.659	54.2908
	101	2	8685.603	15.29677
	101	4	2081.309	16.87018
	101	6	998.7131	13.87935
	101	8	649.4372	13.99873
	101	24	346.2516	13.95302
	101	48	.	28.71129
	101	72	.	74.05039
	101	168	.	848.3252
	101	336	.	8067.568
	101	504	.	5468.969
	101	672	.	5372.655
	101	1536	.	13449.02
	102	0	13795.21	.
	102	0.2333333	15982.51	198.0291
	102	0.5	14861.1	177.7059
	102	1	20085.08	126.4747
	102	2	13626.85	94.33919
	102	4	8116.317	69.99852
	102	6	4144.21	58.01705
	102	8	3665.935	57.12132
	102	24	944.6977	25.69162
	102	48	.	31.92628

Treatment	Subject	Time from dosing (h)	IgG Concentration (mg/L after first dose	IgG Concentration (mg/L)) after second dose
	102	72	.	76.89009
	102	168	.	512.899
	102	336	.	1317.333
	102	504	.	2652.519
	102	672	.	2693.143
	102	1536	.	10634.88
	103	0	6794.282	.
	103	0.2333333	8834.245	119.8499
	103	0.5	8879.973	97.55729
	103	1	4983.838	76.37157
	103	2	4418.58	63.88523
	103	4	1998.4	55.83296
	103	6	1411.941	55.88725
	103	8	880.0089	48.49984
	103	24	550.5551	23.09735
	103	48	.	25.83819
	103	72	.	56.01042
	103	168	.	650.594
	103	336	.	5419.634
	103	504	.	4324.32
	103	672	.	5464.428
	103	1536	.	5224.417
Group 2	201	0	10365.99	.
	201	0.2333333	9720.592	.
	201	0.5	6476.698	.
	201	1	3730.101	.
	201	2	387.9326	.

Treatment	Subject	Time from dosing (h)	IgG Concentration (mg/L after first dose	IgG Concentration (mg/L)) after second dose
	201	4	199.5661	.
	201	6	66.55273	.
	201	8	62.06462	.
	201	24	18.30932	.
	201	48	17.76545	.
	201	72	29.4368	.
	201	168	867.1376	.
	201	336	3433.847	.
	201	504	3766.311	.
	201	672	4393.889	.
	201	1536	6846.651	.
	203	0	10731.55	.
	203	0.2333333	9670.147	34.02811
	203	0.5	4332.385	BLQ 5.00
	203	1	1723.107	10.24965
	203	2	271.8118	0.00562
	203	4	78.57234	BLQ 5.00
	203	6	36.67374	BLQ 5.00
	203	8	29.55301	0.00566
	203	24	BLQ 5.00	BLQ 5.00
	203	48	.	BLQ 5.00
	203	72	.	BLQ 5.00
	203	168	.	1521.019
	203	336	.	2942.506
	203	504	.	25977.62
	203	672	.	4953.073
	203	1536	.	3617.975

Treatment	Subject	Time from dosing (h)	IgG Concentration (mg/L after first dose	IgG Concentration (mg/L)) after second dose
	204	0	7944.695	.
	204	0.2333333	21860.2	.
	204	0.5	4882.952	.
	204	1	3858.67	.
	204	2	1279.177	.
	204	4	379.9424	.
	204	6	125.2956	.
	204	8	117.46	.
	204	24	41.45288	.
	204	48	41.75548	.
	204	72	52.88345	.
	204	168	2385.399	.
	204	336	8285.475	.
	204	504	14473.2	.
	204	672	5937.839	.
	204	1536	8107.741	.
	205	0	8303.145	.
	205	0.2333333	11656.65	30.33635
	205	0.5	6156.182	29.83689
	205	1	2965.897	28.01427
	205	2	829.5142	26.81883
	205	4	1086.246	5.5504
	205	6	306.2605	25.42357
	205	8	294.424	5.24389
	205	24	33.27335	BLQ 5.00
	205	48	.	13.18504
	205	72	.	28.42655

Treatment	Subject	Time from dosing (h)	IgG Concentration (mg/L after first dose	IgG Concentration (mg/L)) after second dose
	205	168	.	112.7609
	205	336	.	8343.447
	205	504	.	7056.815
	205	672	.	6484.355
	205	1536	.	8052.591
Dose interrupted	202	0	9177.513	.
	202	0.2333333	9452.653	.
	202	0.5	8891.279	.
	202	1	8166.482	.
	202	2	8717.907	.
	202	4	8609.533	.
	202	6	13522.16	.
	202	8	18147.12	.
	202	24	8223.725	.
	202	48	11346.58	.
	202	72	11066.81	.
	202	168	5662.981	.
	202	336	5498.206	.
	202	504	5420.176	.
	202	672	29627.35	.
	202	1536	15137.54	.

Norma AB: Anders Nordlund, Date: 2015-06-25, Time: 11:27
Program: P:\HansaMedical\N8713_13-HMed-IdeS-02\STAT\SASPGMLIST\ANAL_PD.sas